Abstract
The purpose of this study was to assess the effectiveness and tolerability of topiramate (TPM) as add-on therapy in children with Dravet syndrome and considered unsatisfactorily controlled using stiripentol. All the 36 patients having been treated with TPM in our centre in 2001 were retrospectively evaluated. Seventy percent of them still received stiripentol when TPM was introduced. The association of both drugs did not need any particular adaptation of dosages. The mean TPM follow-up was 13.3 months (4 - 25 months) and the mean optimal TPM dose was 3.2 mg/kg/d (0.6 - 9.2 mg/kg/d). Twenty eight children (78 %) showed more than 50 % reduction in the frequency of generalized tonic-clonic seizures and status epilepticus (SE), whereas 8 % had more than 50 % increase. Six patients (17 %) remained seizure-free for at least 4 months. The most frequently reported side-effects were gastrointestinal and behavioural disturbances. TPM had to be stopped in 17 % of patients, because of poor tolerability and/or lack of efficacy. Topiramate seems therefore to be helpful in Dravet syndrome, even in patients not satisfactorily controlled by stiripentol. Both drugs can be easily and safely associated.
Key words
Dravet syndrome - topiramate - highly refractory patients
References
-
1
Biton V, Montouris G D, Ritter F, Riviello J J, Reife R, Lim P, Pledger G.
A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group.
Neurology.
1999;
52
1330-1337
-
2 Casse-Perrot C, Wolf M, Dravet C. Neuropsychological aspects of severe myoclonic epilepsy in infancy. Jambaque I, Lassonde M, Dulac O (eds). Neuropsychology of Childhood Epilepsy. New York; Kluwer Academic/Plenum Publisher 2001: 131-140
-
3
Ceulemans B, Boel M, Claes L, Dom L, Willekens H, Thiry P, Lagae L.
Severe myoclonic epilepsy in infancy: toward an optimal treatment.
J Child Neurol.
2004;
19
516-521
-
4
Chiron C, Marchand M C, Tran A, Rey E, d'Athis P, Vincent J, Dulac O, Pons G.
Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.
Lancet.
2000;
356
1638-1642
-
5
Chiron C, Tonnelier S, Rey E, Brunet M L, Tran A, d'Athis P, Vincent J, Dulac O, Pons G.
Stiripentol in childhood partial epilepsy: a randomized placebo-controlled trial with enrichment and withdrawal design.
J Child Neurol.
2006;
21
496-502
-
6
Claes L, Del Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P.
De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy.
Am J Hum Genet.
2001;
68
1327-1332
-
7
Coppola G, Capovilla G, Montagnini A, Romeo A, Spano M, Tortorella G, Veggiotti P, Viri M, Pascotto A.
Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial.
Epilepsy Res.
2002;
49
45-48
-
8 Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy (Dravet syndrome). Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P Epileptic Syndromes in Infancy, Childhood and Adolescence. London; John Libbey 2005: 77-88
-
9
Elterman R D, Glauser T A, Wyllie E, Reife R, Wu S C, Pledger G.
A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group.
Neurology.
1999;
52
1338-1344
-
10
FujiwaraT, Sugawara T, Mazaki-Miyazaki E, Takahashi Y.
Fukushima K. Watanabe M, Hara K, Morikawa T, Yagi K, Yamakawa K, Inoue Y. Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures.
Brain.
2003;
126
531-546
-
11
Mikaeloff Y, Saint-Martin A, Mancini J, Peudenier S, Pedespan J M, Vallee L, Motte J, Bourgeois M, Arzimanoglou A, Dulac O, Chiron C.
Topiramate: efficacy and tolerability in children according to epilepsy syndromes.
Epilepsy Res.
2003;
53
225-232
-
12
Nabbout R, Gennaro E, Dalla B B, Dulac O, Madia F, Bertini E, Capovilla G, Chiron C, Cristofori G, Elia M, Fontana E, Gaggero R, Granata T, Guerrini R, Loi M, La Selva L, Lispi M L, Matricardi A, Romeo A, Tzolas V, Valseriati D, Veggiotti P, Vigevano F, Vallee L, Dagna B F, Bianchi A, Zara F.
Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy.
Neurology.
2003;
60
1961-1967
-
13
Nieto-Barrera M, Candau R, Nieto-Jimenez M, Correa A, del Portal L R.
Topiramate in the treatment of severe myoclonic epilepsy in infancy.
Seizure.
2000;
9
590-594
-
14
Patsalos P N, Perucca E.
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs.
Lancet Neurol.
2003;
2
347-356
-
15
Ritter F, Glauser T A, Elterman R D, Wyllie E.
Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Topiramate YP Study Group.
Epilepsia.
2000;
41 Suppl 1
S82-S85
-
16
Sachdeo R C, Sachdeo S K, Levy R H, Streeter A J, Bishop F E, Kunze K L, Mather G G, Roskos L K, Shen D D, Thummel K E, Trager W F, Curtin C R, Doose D R, Gisclon L G, Bialer M.
Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
Epilepsia.
2002;
43
691-696
-
17
Sugawara T, Mazaki-Miyazaki E, Fukushima K, Shimomura J, Fujiwara T, Hamano S, Inoue Y, Yamakawa K.
Frequent mutations of SCN1A in severe myoclonic epilepsy in infancy.
Neurology.
2002;
58
1122-1124
-
18
Thanh T N, Chiron C, Dellatolas G, Rey E, Pons G, Vincent J, Dulac O.
Efficacité et tolérance à long terme du stiripentol dans le traitement de l'épilepsie myoclonique sévère du nourrisson (syndrome de Dravet).
Arch Pediatr.
2002;
9
1120-1127
-
19
Tran A, Vauzelle-Kervroedan F, Rey E, Pous G, d'Athis P, Chiron C, Dulac O, Renard F, Olive G.
Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children.
Eur J Clin Pharmacol.
1996;
50
497-500
-
20
Tran A, Rey E, Pons G, Rousseau M, d'Athis P, Olive G, Mather G G, Bishop F E, Wurden C J, Labroo R, Trager W F, Kunze K L, Thummel K E, Vincent J C, Gillardin J M, Lepage F, Levy R H.
Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants.
Clin Pharmacol Ther.
1997;
62
490-504
Catherine Chiron
Inserm U663
Service de Neurologie et Metabolisme
Hopital Necker - Enfants Malades
149 rue de Sevres
75015 Paris
France
eMail: catherine.chiron@nck.aphp.fr
